Get notified when MNPR files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsMonopar reports positive Phase 2 results for Wilson disease drug ALXN1840
Filed May 19, 2026 · Period ending May 19, 2026 · ~1 min read
Key Changes
-
high
Phase 2 study showed ALXN1840 (tiomolibdate choline) improves copper balance in Wilson disease patients, a key clinical milestone for this rare genetic disorder treatment.
Item 7.01 Press Release verify on EDGAR → -
high
Results from the ALXN1840-WD-204 study were presented publicly, marking progress in Monopar's pipeline development for this orphan indication.
8-K: Clinical Results verify on EDGAR →
This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (NKE 10-K) is open in full — no account needed.
Partner
Trade MNPR commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 1, 2026 · How we verify